Abstract
The orally active nonpeptide gonadotropin-releasing hormone (GnRH)-receptor antagonist relugolix (Relumina) is being developed by Takeda and ASKA Phar......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
